Incannex Healthcare Inc. (IXHL): R&D Expense
$5.21M
Year ended 2026-06-30
$5.21M
Trailing 12 months to 2026-09-30
-6.2%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $5.21M | -51.5% | 2026-09-25, From 2025-07-01 |
| 2025-06-30 | $10.75M | -16.6% | 2026-09-25, From 2024-07-01 |
| 2024-06-30 | $12.88M | +104.1% | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | $6.31M | n/a | 2024-09-30, From 2022-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $5.21M | -51.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare IXHL, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗